Pharmacokinetics of Faldaprevir of Soft Capsule
- Conditions
- Healthy
- Interventions
- Drug: faldaprevir(high dose)Drug: Faldaprevir(low dose)
- First Posted Date
- 2013-04-01
- Last Posted Date
- 2015-08-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 25
- Registration Number
- NCT01821937
- Locations
- 🇨🇳
1220.52.86001 Boehringer Ingelheim Investigational Site, Beijing, China
ADAM-Afatinib Diarrhea Assessment and Management
- First Posted Date
- 2013-03-20
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 40
- Registration Number
- NCT01814553
- Locations
- 🇺🇸
1200.167.01001 Boehringer Ingelheim Investigational Site, Morristown, New Jersey, United States
🇺🇸1200.167.01009 Boehringer Ingelheim Investigational Site, Santa Rosa, California, United States
🇺🇸1200.167.01020 Boehringer Ingelheim Investigational Site, Orlando, Florida, United States
Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2013-03-15
- Last Posted Date
- 2015-07-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT01811953
- Locations
- 🇩🇪
1276.8.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Preference Tiotropium Respimat Study in COPD
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2013-03-13
- Last Posted Date
- 2015-03-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 150
- Registration Number
- NCT01810692
- Locations
- 🇪🇸
Boehringer Ingelheim Investigational Site 13, A Coruña, Spain
🇪🇸Boehringer Ingelheim Investigational Site 5, Barcelona, Spain
🇪🇸Boehringer Ingelheim Investigational Site 8, Barcelona, Spain
Single Dose Ranging Study of BI 1744 CL (Olodaterol) in Chronic Obstructive Pulmonary Disease
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: single dose of 2 mcgDrug: single dose of 5 mcgDrug: single dose of 10 mcgDrug: single dose of 20 mcgDrug: single dose of 40 mcgDrug: single dose of placebo
- First Posted Date
- 2013-03-12
- Last Posted Date
- 2014-06-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT01809262
- Locations
- 🇳🇱
1222.3.1 Atrium medisch centrum, Heerlen, Netherlands
Investigation of Interactions Between Faldaprevir, Itraconazole, Atorvastatin and Rosuvastatin
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2013-02-21
- Last Posted Date
- 2015-08-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 51
- Registration Number
- NCT01795937
- Locations
- 🇩🇪
1220.61.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
- First Posted Date
- 2013-02-15
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 360
- Registration Number
- NCT01792518
- Locations
- 🇻🇳
Boehringer Ingelheim Investigational Site, Ho Chi Minh City, Vietnam
Drug-drug Interaction Trial of BI 113608 in Combination With Ketoconazole and Voriconazole in Healthy Male Subjects
- First Posted Date
- 2013-02-08
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT01787032
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site, Ingelheim, Germany
Investigation of Faldaprevir Effect on Pharmacokinetics of Raltegravir
- First Posted Date
- 2013-02-07
- Last Posted Date
- 2015-08-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 25
- Registration Number
- NCT01785160
- Locations
- 🇩🇪
1220.65.1 Boehringer Ingelheim Investigational Site, Mannheim, Germany
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2013-01-29
- Last Posted Date
- 2016-04-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 708
- Registration Number
- NCT01778049
- Locations
- 🇵🇹
1275.10.35104 Boehringer Ingelheim Investigational Site, Cantanhede, Portugal
🇵🇹1275.10.35112 Boehringer Ingelheim Investigational Site, Porto, Portugal
🇺🇦1275.10.38002 Boehringer Ingelheim Investigational Site, Kiev, Ukraine